An Integrated Study to Extrapolate the Interaction of Nmdar with Potential Ligands for the Treatment of Alzheimer’s Disease Symptoms.

Year : 2023 | Volume : 01 | Issue : 01 | Page : 16-28

    Varsini S.R.

  1. Samiksha Shivaji Bhor

  1. Student, Department of Biotechnology, School of Bio-Science and Technology, VIT University, Vellore, 632014, India
  2. Bioinformatics Associate, Department of Biotechnology, BioNome, Bengaluru, India


Objective: Alzheimer’s disease (AD) is the most common neurodegenerative disease affecting the health status of older adults especially those above the age of 60 years. As an outcome, two types of medications have been developed for the treatment of its symptoms which are acetylcholinesterase (AChE) and N – methyl -D -aspartate receptor (NMDAR) antagonist. This paper uses the computational approach for understanding the interaction of NMDAR with 4 major phytocompounds (Curcumin, L-epicatechin, Ginsenosides, and Resveratrol) by molecular docking NMDAR against the ligands. Then their therapeutic analysis and pharmacological characteristics were investigated. Method: In this study, the target protein NMDAR was retrieved from PDB and docked against 6 phytocompounds via PyRx. The binding affinity of the target protein with each ligand was compared and analysed. Out of the 6 phytocompounds the top 4 phytocompounds were selected based on their binding affinity, which had to be lower than 6. The top 4 were then studied using ADMET and visualised using BIOVIA Discovery Studio Visualizer. Results: Molecular docking results of the target protein, NMDAR, with the top 4 ligands (Curcumin, L-epicatechin, Ginsenosides, and Resveratrol) showed that these ligands have the best binding affinity with the target protein. Conclusion: By analysing the results it can be concluded that the top 4 ligands (Curcumin, L-epicatechin, Ginsenosides, and Resveratrol) can be used for the treatment of AD symptoms. But, ligands in vitro and in vivo studies have to be carried out to understand the practical use of these ligands.

Keywords: Alzheimer’s disease (AD), N – methyl -D -aspartate receptor (NMDAR), Curcumin, L-epicatechin, Ginsenosides, Resveratrol, molecular docking, ADMET.

[This article belongs to International Journal of Biochemistry and Biomolecule Research(ijbbr)]

How to cite this article: Varsini S.R., Samiksha Shivaji Bhor An Integrated Study to Extrapolate the Interaction of Nmdar with Potential Ligands for the Treatment of Alzheimer’s Disease Symptoms. ijbbr 2023; 01:16-28
How to cite this URL: Varsini S.R., Samiksha Shivaji Bhor An Integrated Study to Extrapolate the Interaction of Nmdar with Potential Ligands for the Treatment of Alzheimer’s Disease Symptoms. ijbbr 2023 {cited 2023 May 10};01:16-28. Available from:

Browse Figures


  1. Monica Moore, M., Díaz-Santos, M., & Vossel, K. Alzheimer’s Association 2021 Facts and Figures Report. Alzheimer’s Association.
  2. Mishra, S., & Palanivelu, K. (2008). The effect of curcumin (turmeric) on Alzheimer’s disease: An overview. Annals of Indian Academy of Neurology, 11(1), 13.
  3. Newcomer, J. W., Farber, N. B., & Olney, J. W. (2022). NMDA receptor function, memory, and brain aging. Dialogues in clinical neuroscience.
  4. Cascella, M., Bimonte, S., Muzio, M. R., Schiavone, V., & Cuomo, A. (2017). The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: An overview of pre-clinical studies and translational perspectives in clinical practice. Infectious agents and cancer, 12(1), 1-7.
  5. Chacko, S. M., Thambi, P. T., Kuttan, R., & Nishigaki, I. (2010). Beneficial effects of green tea: a literature review. Chinese medicine, 5(1), 1-9.
  6. Ide, K., Matsuoka, N., Yamada, H., Furushima, D., & Kawakami, K. (2018). Effects of tea catechins on Alzheimer’s disease: Recent updates and perspectives. Molecules, 23(9), 2357.
  7. Lee, Y. J., Choi, D. Y., Yun, Y. P., Han, S. B., Oh, K. W., & Hong, J. T. (2013). Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties. The Journal of nutritional biochemistry, 24(1), 298-310.
  8. Morales, I., Guzmán-Martínez, L., Cerda-Troncoso, C., Farías, G. A., & Maccioni, R. B. (2014). Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches. Frontiers in cellular neuroscience, 8, 112.
  9. Wang, N., Yang, J., Chen, R., Liu, Y., Liu, S., Pan, Y., … & Li, Z. (2022). Ginsenoside Rg1 ameliorates Alzheimer’s disease pathology via restoring mitophagy. Journal of Ginseng Research.
  10. Al-Bishri, W. M., Hamza, A. H., & Farran, S. K. (2017). Resveratrol Treatment Attenuates Amyloid Beta, Tau Protein and Markers of Oxidative Stress, and Inflammation in Alzheimer’s disease Rat Model. International Journal of Pharmaceutical Research & Allied Sciences, 6(3).
  11. Rahman, M., Akter, R., Bhattacharya, T., Abdel-Daim, M. M., Alkahtani, S., Arafah, M. W., … & Mittal, V. (2020). Resveratrol and neuroprotection: impact and its therapeutic potential in Alzheimer’s disease. Frontiers in pharmacology, 2272.
  12. Scheltens, P., Blennow, K., Breteler, M. M., De Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016). Alzheimer’s disease. The Lancet, 388(10043), 505-517.
  13. Bye, L. J., Finol-Urdaneta, R. K., Tae, H. S., & Adams, D. J. (2023). Nicotinic acetylcholine receptors: key targets for attenuating neurodegenerative diseases. The International Journal of Biochemistry & Cell Biology, 106387.
  14. Uddin, M. S., Al Mamun, A., Kabir, M. T., Ashraf, G. M., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2021). Multi-target drug candidates for multifactorial Alzheimer’s disease: AChE and NMDAR as molecular targets. Molecular Neurobiology, 58, 281-303.
  15. Danysz, W., & Parsons, C. G. (2012). Alzheimer’s disease, beta-amyloid, glutamate, NMDA receptors and memantine–searching for the connections. British journal of pharmacology, 167(2), 324-352.
  16. Cohen, S. M., Ma, H., Kuchibhotla, K. V., Watson, B. O., Buzsáki, G., & Froemke, R. C. (2015). Excitation–inhibition imbalance leads to hippocampal hyperexcitability and impaired cognition in a mouse model of Alzheimer’s disease. Neuron, 83(6), 1382-1393.
  17. Parsons, M. P., & Raymond, L. A. (2014). Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron, 82(2), 279-293.
  18. Feng, T., Wei, Y., Lee, R. J., Zhao, L., & Yu, S. P. (2019). The role of TRPM7 channels in neuronal cell apoptosis and necrosis. Brain research bulletin, 151, 151-158.
  19. Rezai‐Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., … & Tan, J. (2008). Green tea epigallocatechin‐3‐gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. Journal of Neuroscience, 28(51), 11500-11510.
  20. Li, Q. S., Li, X. Y., Duan, X. L., Yang, Y., Liu, F., Yuan, Y. H., … & Chen, N. H. (2013). Epigallocatechin‐3‐gallate attenuates cognitive deterioration in Alzheimer’s disease model mice by upregulating neprilysin expression. Experimental cell research, 319(5), 704-713.
  21. Jia, J. P., Li, X., & Li, Y. J. (2004). Ginsenoside Rg1 enhances NMDA receptor-mediated synaptic transmission in hippocampal CA1 area of rats. Sheng li xue bao: [Acta physiologica Sinica], 56(2), 139-144.
  22. Jang, H. J., Nam, J. H., Oh, J. H., Lee, J. H., & Kim, J. K. (2015). Ginsenoside Rb1 enhances N-methyl-D-aspartate receptor-mediated long-term potentiation and improves memory performance in aged rats. Physiology & behavior, 147, 183-191.
  23. Chen, C., Yu, R., Owuor, E. D., & Kong, A. N. (2011). Activation of Nrf2/ARE pathway by resveratrol protects against oxidative stress-induced neuronal cell death in NSC-34 cells. Molecular and cellular biochemistry, 357(1-2), 241-251.
  24. Vingtdeux, V., Giliberto, L., Zhao, H., Chandakkar, P., Wu, Q., Simon, J. E., & Marambaud, P. (2010). AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-β peptide metabolism. Journal of Biological Chemistry, 285(12), 9100-9113.

Regular Issue Subscription Original Research
Volume 01
Issue 01
Received April 13, 2023
Accepted April 29, 2023
Published May 10, 2023